BG758Y1 - Combined preparation for methadone therapy - Google Patents

Abstract

The preparation can be used for methadone therapy in addict patients for extending the therapeutic potentials and discovering new methadone programmes. It ensures complex effect by the administrationof only one preparation, which is of particular importance with a view to the patients' special psychological set up. It comprises methadone and dry extract of St. John's wort, standardized after hyperacine in ratio from 1:1 to 1:10. With the preparation, according to the utility model some of the side effect of the methadone are eliminated, such as constipation, nausea and vomiting, metabolic impairment, the side effect of the methadone on sexual desire and behaviour is reduced, there is synergic effect on the central nervous system without any risk of additional suppression of the centre ofbreathing, depressive conditions are affected and worry is reduced, and physiologic sleep is improved.

Description

(54) COMBINED METHODONE THERAPY

Technical field

The utility model relates to a new combination drug for methadone therapy in addicted patients to expand treatment options and open new methadone programs.

BACKGROUND OF THE INVENTION

Methadone is the generic name for the compound 6-dimegylamino-4,4-diphenyl-3-hepatone hydrochloride. It is a white crystalline powder that melts at 233 - 236 ° C. It is soluble in water, ethanol, chloroform. It is insoluble in ether. The methadone molecule has two independent active groups: the nitrogen atom attached to the hydrochloride groups at one end affects the peripheral nervous system, the two phenyl rings having an effect on the central nervous system, similar to natural opioids. Since the creation of methadone in 1942 [DE 711 069] and the development of the first program for the maintenance treatment of opiate addiction by Marie Nyawander and Vincent Dole so far, continuous research has been conducted, various methadone administration programs developed and experimented with concomitant activities and various dosage forms for its introduction into the body [Andrew Preston, Methadone Treatment, short practical guide].

Methadone is produced in various dosage forms - solutions and tablets for oral use and ampoules for injection.

In the administration of methadone, the most common side effects are depression in patients and gastrointestinal disorders [Ekkehard Madluns-Kratzer, Frank Altenstrassen, Psychopraxis, 4/01]. When combined with other medicines such as codeine, barbiturates and phenothiazines, there is a risk of depression in the respiratory center due to their synergistic effect with methadone.

There is no known combination drug on the basis of methadone to reduce its side effects.

Given these problems with the use of the various known oral methadone forms, the utility of the utility model is to develop a methadone combination therapy that minimizes the side effects of its self-administration, increasing its effect on the CNS, avoiding further depression on the CNS the center of respiration, as well as being able to be administered without problems in the patient's unwillingness, to be quickly effective, with rapid plasma concentration, and not to cause storage problems.

The technical nature of the utility model

According to the utility model, these problems are solved with a combination preparation consisting of methadone and dry extract of Hypericum perforatum (St. John's wort) in a ratio of 1: 1 to 1:10.

The benefits of the combination drug are that it eliminates some of the side effects of methadone - constipation, nausea and vomiting, metabolic disorders, reduced side effects of methadone on sexual desire and behavior, and a synergistic effect on CNS without the risk of further depression of the center of breathing, depressive states are affected and anxiety is reduced, and physiological sleep is improved.

The utility model provides a complex effect with the administration of a single drug, which is of particular importance in view of the particular psychological adjustment of this contingent of patients. The presence of dried St. John's wort extract makes intravenous injection impossible due to the inability to make a "boil". The combination preparation may be formulated in various suitable dosage forms, preferably rapidly soluble oral forms.

Exemplary implementation of the utility model

Example 1. Preparation containing 10 mg methadone and 40 mg dry St. John's wort extract standardized on hyperacin.

Example 2. Preparation containing 30 mg methadone and 40 mg dry St. John's wort extract standardized for hyperacin.

Example 3. Preparation containing 50 mg methadone and 80 mg dry St. John's wort extract standardized for hyperacin.

Example 4. Preparation containing 10 mg methadone and 60 mg dry St. John's wort extract standardized for hyperacin.

Example 5. Preparation containing 30 mg methadone and 60 mg dry St. John's wort extract standardized for hyperacin.

Example 6. Preparation containing 30 mg methadone and 80 mg dry St. John's wort extract standardized on hyperacin.

Example 7. Preparation containing 50 mg methadone and 100 mg dry St. John's wort extract standardized on hyperacin.

Claims (1)

Claims A combination methadone therapy preparation comprising 10 methadone and a dry extract of Hypericum perforatum standardized by hyperacin in a ratio of 1: 1 to 1: 10.